newsfilter
← Latest News
GlobeNewswire·

Nyxoah Receives $15 Million from the European Investment Bank

  • Nyxoah received $15 million (€13.8 million) from the second tranche of its loan facility with the European Investment Bank (EIB).
  • This non-dilutive debt funding complements a June equity raise, bringing Nyxoah's total new capital raised in June 2026 to approximately $110 million.
  • The EIB proceeds will primarily accelerate the commercial launch of the Genio system in the United States while supporting research, development, & manufacturing scale-up.
  • The funding reinforces Nyxoah's balance sheet without diluting existing shareholders.
  • Nyxoah's Genio system received CE Mark approval in 2019 & FDA approval in August 2025 for adult patients with moderate to severe Obstructive Sleep Apnea (OSA).